.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for inclusion of individuals along with MASLD and dimension of liver outcomes in cardio-- kidney-- metabolic trials, when records advise mechanistically tenable perks and clinical safety-- and describes considerations for trial concept and regulatory commendation.